Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACAT2 | Q9BWD1 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516760 | 0.88 | ACAT2 (0.78) | ACAT2C3AR1GRIN2BTACR1CYP2C9 | |
| SCHEMBL16410830 | 0.73 | ACAT2 (0.57) | ACAT2SLC6A2SLC6A4C3AR1GRIN2B | |
| SCHEMBL17757269 | 0.72 | ACAT2 (0.56) | ACAT2SLC6A2SLC6A4TACR1HTR2C | |
| SCHEMBL17757951 | 0.72 | ACAT2 (0.56) | ACAT2SLC6A2SLC6A4HTR2CCYP2C9 | |
| SCHEMBL17757952 | 0.72 | ACAT2 (0.56) | ACAT2SLC6A2SLC6A4GRIN2BHTR3E | |
| SCHEMBL17757274 | 0.71 | ACAT2 (0.54) | ACAT2SLC6A2SLC6A4HTR2CHTR2B | |
| SCHEMBL21982537 | 0.71 | ACAT2 (0.54) | ACAT2SLC6A2SLC6A4HTR3AHTR2C | |
| SCHEMBL17757973 | 0.71 | ACAT2 (0.54) | ACAT2SLC6A2SLC6A4GRIN2BHTR3E | |
| SCHEMBL17757267 | 0.70 | ACAT2 (0.53) | ACAT2SLC6A2SLC6A4HTR3ATACR1 | |
| SCHEMBL17757281 | 0.69 | ACAT2 (0.53) | ACAT2C3AR1HTR2CHTR2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080099-A | Amphiphilic nicotinamide adenine dinucleotide conjugate, nano micelle and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-4739297-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| CN-120154614-A | New application of iron death inhibitor | 四川农业大学 | 2025-06-17 | — | — | CN | claimed |
| CN-119656319-A | Iron death inhibitors for improving liver toxicity of GPR40 agonist TAK-875 | 张宏全 | 2025-03-21 | — | — | CN | claimed |
| WO-2025012669-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012152-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| US-20250009696-A1 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | CORNELL UNIVERSITY | 2025-01-09 | — | — | US | claimed |
| CN-119097703-A | Application of iron death inhibitor in preparation of anti-novel bunyavirus drugs | 中国人民解放军军事科学院军事医学研究院 | 2024-12-10 | — | — | CN | claimed |
| CN-119055780-A | Application of iron death inhibitor combined with KRAS inhibitor in preparation of medicine for treating KRAS mutant tumor and medicine composition | 四川大学华西医院 | 2024-12-03 | — | — | CN | claimed |
| EP-4460299-A2 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| CN-116036087-A | Use of iron death inhibitor in preparing medicine for repairing damaged liver | 中国人民解放军空军军医大学 | 2023-05-02 | — | — | CN | claimed |
| CN-115804772-A | Application of iron death inhibitor in resisting virus infection | 山东大学 | 2023-03-17 | — | — | CN | claimed |
| WO-2023277250-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING KIDNEY AGING, COMPRISING LIPROXSTATIN-1 AS ACTIVE INGREDIENT | 가톨릭대학교 산학협력단 | 2023-01-05 | — | — | WO | claimed |
| CN-115261327-A | Immune cell based on iron death inhibitor and preparation method and application thereof | 浙江大学医学院附属第一医院 | 2022-11-01 | — | — | CN | claimed |
| CN-115120595-A | Application of Liproxstatin-1 in preparation of medicine for preventing and treating leukemia and pharmaceutical composition thereof | 广西医科大学第一附属医院 | 2022-09-30 | — | — | CN | claimed |
| CN-114903997-A | Application of iron death inhibitor in preparation of medicine for preventing and treating male reproductive dysfunction | 北京大学第三医院（北京大学第三临床医学院） | 2022-08-16 | — | — | CN | claimed |
| US-20220193275-A1 | INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-23 | — | — | US | claimed |
| CN-114606192-A | Kras/Lkb1 mutant non-small cell lung cancer organoid culture solution and culture method | 南方医科大学南方医院 | 2022-06-10 | — | — | CN | claimed |
| WO-2022115641-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| CN-114377016-A | Application of Liproxstatin-1 in preparation of medicine for preventing and treating aortic dissection and pharmaceutical composition thereof | 华中科技大学同济医学院附属同济医院 | 2022-04-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009696-A1 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | AIFM2, GPX1, GPX4 | ACAT2 2589/4885SLC6A2 3693/4885SLC6A4 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.